Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin QT interval study
NCT00786838Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2008
- Primary completion
- Dec 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 7
01
Overview
Phase 2, single-blind, single-arm trial of trabectedin in solid tumor, sponsored by Johnson & Johnson. Primary endpoints: Difference in the Change From Baseline in QTc Intervals Trabectedin Relative to Placebo by Fridericia Correction and Difference in the Change From Baseline in QTc Intervals Trabectedin Relative to Placebo by Bazett's Correction. Started Oct 2008; status: completed.
02
Drugs
trabectedin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT00786838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00786838.